Wird geladen...
Losartan and end‐organ protection—lessons from the renaal study
Background: The Reduction in ENdpoints with the Angiotensin Antagonist Losartan (RENAAL) study reported that losartan delayed the progression of renal disease in patients with type 2 diabetes and nephropathy. Diabetic or renally impaired patients are at high cardiovascular risk, a risk potentially i...
Gespeichert in:
| Veröffentlicht in: | Clin Cardiol |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Wiley Periodicals, Inc.
2006
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654430/ https://ncbi.nlm.nih.gov/pubmed/15813620 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960280307 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|